Newron Pharmaceuticals SpA has reached a licensing agreement with Merck Serono to investigate the potential of two Merck clinical-stage compounds for disorders of the central nervous system. Financial terms weren’t disclosed. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
